Page 58 - TD-2-2

Tumor Discovery Choroid plexus tumors: Benign to malignant

https://doi.org/10.1159/000528792 https://doi.org/10.3389/FPHAR.2023.1130937/BIBTEX
124. Morimoto T, Nakazawa T, Maeoka R, et al., 2023, Natural 134. Fang X, Lan H, Jin K, et al., 2022, Nanovaccines for cancer
killer cell-based immunotherapy against glioblastoma. Int J prevention and immunotherapy: An update review. Cancers
Mol Sci, 24(3): 2111. (Basel), 14(16): 3842.
https://doi.org/10.3390/IJMS24032111 https://doi.org/10.3390/cancers14163842
126. Xiao Y, Yu D, 2021, Tumor microenvironment as a 135. Zhang Y, Lin S, Wang XY, et al., 2019, Nanovaccines for
therapeutic target in cancer. Pharmacol Ther, 221: 107753. cancer immunotherapy. Wiley Interdiscip Rev Nanomed
Nanobiotechnol, 11(5): e1559.
https://doi.org/10.1016/j.pharmthera.2020.107753
https://doi.org/10.1002/WNAN.1559
126. Pollack IF, Jakacki RI, Butterfield LH, et al., 2014, Antigen-
specific immune responses and clinical outcome after 136. Guo S, Feng J, Li Z, et al., 2023, Improved cancer
vaccination with glioma-associated antigen peptides and immunotherapy strategies by nanomedicine. Wiley
polyinosinic-polycytidylic acid stabilized by lysine and Interdiscip Rev Nanomed Nanobiotechnol, 15(3): e1873.
carboxymethylcellulose in children with newly diagnosed https://doi.org/10.1002/WNAN.1873
malignant brainstem and nonbrainstem gliomas. J Clin
Oncol, 32(19): 2050–2058. 137. Yang J, Zhang C, 2020, Regulation of cancer-immunity
cycle and tumor microenvironment by nanobiomaterials
https://doi.org/10.1200/JCO.2013.54.0526 to enhance tumor immunotherapy. Wiley Interdiscip Rev
127. Pollack IF, Jakacki RI, Butterfield LH, et al., 2016, Immune Nanomed Nanobiotechnol, 12(4): e1612.
responses and outcome after vaccination with glioma- https://doi.org/10.1002/WNAN.1612
associated antigen peptides and poly-ICLC in a pilot study
for pediatric recurrent low-grade gliomas. Neuro Oncol, 138. Böttcher JP, Bonavita E, Chakravarty P, et al., 2018,
18(8): 1157–1168. NK cells stimulate recruitment of cDC1 into the tumor
microenvironment promoting cancer immune control. Cell,
https://doi.org/10.1093/neuonc/now026 172(5): 1022–1037.e14.
128. Pollack IF, Jakacki RI, Butterfield LH, et al., 2016, Antigen- https://doi.org/10.1016/J.CELL.2018.01.004
specific immunoreactivity and clinical outcome following
vaccination with glioma-associated antigen peptides in 139. Zhou X, Yu J, Cheng X, et al., 2019, The deubiquitinase
children with recurrent high-grade gliomas: Results of a Otub1 controls the activation of CD8+ T cells and NK
pilot study. J Neurooncol, 130(3): 517–527. cells by regulating IL-15-mediated priming. Nat Immunol,
20(7): 879–889.
https://doi.org/10.1007/S11060-016-2245-3 https://doi.org/10.1038/S41590-019-0405-2
129. Home - ClinicalTrials.gov. Available from: https:// 140. Klemm F, Maas RR, Bowman RL, et al., 2020, Interrogation
clinicaltrials.gov [Last accessed on 2023 May .
25]
of the microenvironmental landscape in brain tumors
130. NCT00014573, 2013, Chemotherapy and Vaccine reveals disease-specific alterations of immune cells. Cell,
Therapy Followed by Bone Marrow or Peripheral Stem 181(7): 1643–1660.e17.
Cell Transplantation and Interleukin-2 in Treating https://doi.org/10.1016/J.CELL.2020.05.007
Patients With Recurrent or Refractory Brain Cancer - Full
Text View - ClinicalTrials.gov. Available from: https:// 141. Grabowski MM, Sankey EW, Ryan KJ, et al., 2021, Immune
clinicaltrials.gov/ct2/show/nct00014573 [Last accessed on suppression in gliomas. J Neurooncol, 151(1): 3–12.
2023 May . https://doi.org/10.1007/S11060-020-03483-Y
25]
131. Donninger H, Li C, Eaton JW, et al., 2021, Cancer vaccines: 142. Louveau A, Harris TH, Kipnis J, 2015, Revisiting the
Promising therapeutics or an unattainable dream. Vaccines mechanisms of CNS immune privilege. Trends Immunol,
(Basel), 9(6): 668. 36(10): 569–577.
https://doi.org/10.3390/VACCINES9060668 https://doi.org/10.1016/J.IT.2015.08.006
132. He X, Zhang S, Tian Y, et al., 2023, Research progress of 143. Romero-Suárez S, Del Rio Serrato A, Bueno RJ, et al., 2019,
nanomedicine-based mild photothermal therapy in tumor. The central nervous system contains ILC1s that differ from
Int J Nanomedicine, 18: 1433–1468. NK cells in the response to inflammation. Front Immunol,
https://doi.org/10.2147/IJN.S405020 10: 2337.
133. Zhang X, Wang X, Hou L, et al., 2023, Nanoparticles https://doi.org/10.3389/FIMMU.2019.02337
overcome adaptive immune resistance and enhance 144. Calmeiro J, Carrascal MA, Tavares AR, et al., 2020, Dendritic
immunotherapy via targeting tumor microenvironment in cell vaccines for cancer immunotherapy: The role of
lung cancer. Front Pharmacol, 14: 824. human conventional Type 1 dendritic cells. Pharmaceutics,

Volume 2 Issue 2 (2023) 16 https://doi.org/10.36922/td.1057